Kai‐Keen Shiu

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

Thierry André, Kai‐Keen Shiu, Tae Won Kim et al. · New England Journal of Medicine · 2020 · 3K citations · Full text

Medicine, Oncology, Pharmacology +17

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

Luis A. Díaz, Kai‐Keen Shiu, Tae‐Won Kim et al. · The Lancet Oncology · 2022 · 894 citations · Full text

Medicine, Oncology, Chemotherapy +14

Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study.

Thierry André, Kai‐Keen Shiu, Tae Won Kim et al. · Journal of Clinical Oncology · 2020 · 197 citations

Medicine, Oncology, Pharmacology +17

Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple‐negative and basal‐like breast cancers

Daniel Wetterskog, M. Ángeles López‐García, Maryou B. Lambros et al. · The Journal of Pathology · 2011 · 167 citations

Life Sciences, Genetics, Oncology +17

Functional Viability Profiles of Breast Cancer

Rachel Brough, Jessica Frankum, David Sims et al. · Cancer Discovery · 2011 · 143 citations · Full text

Pharmacy, Molecular Biology, Oncology +15